Deal Tracker · Regions

CIS & Central Asia pharma localization & tech-transfer deals

7 technology transfer / localization deals in the CIS & Central Asia tracked by EPT (2026). Most active: Kazakhstan Ministry of Health, Abdi İbrahim, Abdi Ibrahim Global Pharm & AltINFARM. Latest: Sanofi → Nobel AFF (Technology transfer / Localization, 26 Oct 2026).

7
deals tracked
4
countries involved
$530.7m
disclosed value (6 deals)
100%
localization, the top deal type
  • EPT has tracked 7 CIS & Central Asia pharma localization & tech-transfer deals (2026).
  • The countries that appear most often are Kazakhstan (7), Türkiye (2), China (1) & France (1).
  • Values were disclosed for 6 of 7 deals, totalling $530.7m; the largest is Sinopharm, Sinovac & Kangtai Biological Technology → AltINFARM ($125m, 22 Jan 2026).
  • The most active companies: Kazakhstan Ministry of Health (2).

Most active companies

Kazakhstan Ministry of Health (2)

Countries involved

Kazakhstan (7) · Türkiye (2) · China (1) · France (1)

Largest disclosed deals

Questions

How many CIS & Central Asia pharma localization & tech-transfer deals has EPT tracked?
7 as of 26 Oct 2026, covering 2026. The most recent is Sanofi → Nobel AFF (Technology transfer / Localization, 26 Oct 2026).
Which companies are most active in CIS & Central Asia pharma localization & tech-transfer deals?
Kazakhstan Ministry of Health (2 deals).
What is the largest disclosed CIS & Central Asia pharma localization & tech-transfer deal?
Sinopharm, Sinovac & Kangtai Biological Technology → AltINFARM: $125m (Technology transfer / Localization, 22 Jan 2026); Kazakhstan Ministry of Health → Karaganda Pharmaceutical Complex: $89.7m (Technology transfer / Localization, 15 May 2026); Nobel İlaç → Nobel Almaty Pharmaceutical Factory: $84m (Technology transfer / Localization, 22 Jan 2026). Values are as announced by the parties.
Which countries appear most in CIS & Central Asia pharma localization & tech-transfer deals?
Kazakhstan (7), Türkiye (2), China (1), France (1) — counting where the parties are based and the markets the deals cover.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)